Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $0.00 to $27.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $14.60, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 84.93% | Cantor Fitzgerald | → $27 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 84.93% | Cantor Fitzgerald | $25 → $27 | Maintains | Overweight |
| 08/11/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 07/21/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/21/2023 | 64.38% | Truist Securities | $22 → $24 | Maintains | Buy |
| 06/21/2023 | 71.23% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 64.38% | Truist Securities | $22 → $24 | Maintains | Buy |
| 05/12/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 03/20/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 01/19/2023 | 50.68% | Truist Securities | $18 → $22 | Maintains | Buy |
| 12/21/2022 | 23.29% | Truist Securities | $17 → $18 | Maintains | Buy |
| 12/21/2022 | 64.38% | HC Wainwright & Co. | $18 → $24 | Maintains | Buy |
| 12/20/2022 | 36.99% | Piper Sandler | $18 → $20 | Maintains | Overweight |
| 08/24/2022 | 6.16% | Roth Capital | $10 → $15.5 | Downgrades | Buy → Neutral |
| 08/11/2022 | 16.44% | Truist Securities | $12 → $17 | Maintains | Buy |
| 08/11/2022 | 23.29% | HC Wainwright & Co. | $12 → $18 | Maintains | Buy |
| 02/08/2022 | -17.81% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 03/18/2021 | -52.05% | Roth Capital | $6.5 → $7 | Maintains | Buy |
| 08/12/2020 | -45.21% | Truist Securities | $10 → $8 | Maintains | Buy |
| 05/13/2020 | -31.51% | SunTrust Robinson Humphrey | $11 → $10 | Maintains | Buy |
| 02/14/2020 | -17.81% | Cantor Fitzgerald | $11 → $12 | Reiterates | → Overweight |
| 12/13/2018 | -48.63% | Piper Sandler | $5 → $7.5 | Maintains | Overweight |
| 11/29/2018 | -45.21% | Cantor Fitzgerald | → $8 | Reiterates | → Overweight |
| 09/21/2018 | -45.21% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/22/2023 | 84.93% | 坎託·菲茨傑拉德 | → 27 美元 | 重申 | 超重 → 超重 |
| 08/11/2023 | 84.93% | 坎託·菲茨傑拉德 | 25 美元 → 27 美元 | 維護 | 超重 |
| 08/11/2023 | 64.38% | HC Wainwright & Co. | → 24 美元 | 重申 | 購買 → 購買 |
| 07/21/2023 | 64.38% | HC Wainwright & Co. | → 24 美元 | 重申 | 購買 → 購買 |
| 06/21/2023 | 64.38% | 信託證券 | 22 美元 → 24 美元 | 維護 | 購買 |
| 06/21/2023 | 71.23% | 坎託·菲茨傑拉德 | → 25 美元 | 重申 | 超重 → 超重 |
| 06/20/2023 | 64.38% | 信託證券 | 22 美元 → 24 美元 | 維護 | 購買 |
| 05/12/2023 | 64.38% | HC Wainwright & Co. | → 24 美元 | 重申 | 購買 → 購買 |
| 03/20/2023 | 64.38% | HC Wainwright & Co. | → 24 美元 | 重申 | → 購買 |
| 01/19/2023 | 50.68% | 信託證券 | 18 美元 → 22 美元 | 維護 | 購買 |
| 2022 年 12 月 21 日 | 23.29% | 信託證券 | 17 美元 → 18 美元 | 維護 | 購買 |
| 2022 年 12 月 21 日 | 64.38% | HC Wainwright & Co. | 18 美元 → 24 美元 | 維護 | 購買 |
| 2022 年 12 月 20 日 | 36.99% | 派珀·桑德勒 | 18 美元 → 20 美元 | 維護 | 超重 |
| 2022 年 8 月 24 日 | 6.16% | 羅斯資本 | 10 美元 → 15.5 美元 | 降級 | 買入 → 中性 |
| 08/11/2022 | 16.44% | 信託證券 | 12 美元 → 17 美元 | 維護 | 購買 |
| 08/11/2022 | 23.29% | HC Wainwright & Co. | 12 美元 → 18 美元 | 維護 | 購買 |
| 2022 年 8 月 2 日 | -17.81% | HC Wainwright & Co. | 9 美元 → 12 美元 | 維護 | 購買 |
| 03/18/2021 | -52.05% | 羅斯資本 | 6.5 美元 → 7 美元 | 維護 | 購買 |
| 08/12/2020 | -45.21% | 信託證券 | 10 美元 → 8 美元 | 維護 | 購買 |
| 05/13/2020 | -31.51% | SunTrust 羅賓遜漢弗萊 | 11 美元 → 10 美元 | 維護 | 購買 |
| 02/14/2020 | -17.81% | 坎託·菲茨傑拉德 | 11 美元 → 12 美元 | 重申 | → 超重 |
| 2018 年 12 月 13 日 | -48.63% | 派珀·桑德勒 | 5 美元 → 7.5 美元 | 維護 | 超重 |
| 11/29/2018 | -45.21% | 坎託·菲茨傑拉德 | → 8 美元 | 重申 | → 超重 |
| 09/21/2018 | -45.21% | 坎託·菲茨傑拉德 | → 8 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmicals（CPRX）的目標價格是多少？
The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $27.00 expecting CPRX to rise to within 12 months (a possible 84.93% upside). 14 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月22日公佈了Catalyst Pharmicals（納斯達克股票代碼：CPRX）的最新目標股價。該分析公司將目標股價定爲27.00美元，預計CPRX將在12個月內升至12個月內（可能上漲84.93％）。去年有14家分析公司公佈了評級。
What is the most recent analyst rating for Catalyst Pharmaceuticals (CPRX)?
分析師對Catalyst Pharmicals（CPRX）的最新評級是多少？
The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ: CPRX) was provided by Cantor Fitzgerald, and Catalyst Pharmaceuticals reiterated their overweight rating.
Catalyst Pharmicals（納斯達克股票代碼：CPRX）的最新分析師評級由坎託·菲茨傑拉德提供，Catalyst Pharmicals重申了其增持評級。
When is the next analyst rating going to be posted or updated for Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmicals（CPRX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Catalyst Pharmicals的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Catalyst Pharmicals的最後一次評級是在2023年8月22日提交的，因此你應該預計下一個評級將在2024年8月22日左右公佈。
Is the Analyst Rating Catalyst Pharmaceuticals (CPRX) correct?
分析師對 Catalyst Pharmicals (CPRX) 的評級正確嗎？
While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $0.00 to $27.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $14.60, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Catalyst Pharmicals（CPRX）評級，目標股價爲0.00美元至27.00美元。Catalyst Pharmicals（CPRX）目前的交易價格爲14.60美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。
